Therapeutic targets for diabetic nephropathy identified by druggable genome mendelian randomization: the role of the gut microbiota-metabolite axis - Takeaways - MDSpire

Therapeutic targets for diabetic nephropathy identified by druggable genome mendelian randomization: the role of the gut microbiota-metabolite axis

  • By

  • Ling Niu

  • Rong Ma

  • Cuijuan Miao

  • Fang Liu

  • Boyi Li

  • May 8, 2026

  • 0 min

Share

  • 1

    Diabetic nephropathy (DN) affects approximately 40% of type 2 diabetes patients and is a leading cause of end-stage renal disease.

  • 2

    The study identified 8,913 differentially expressed genes, with 1,263 genes potentially involved in DN pathogenesis and as drug targets.

  • 3

    FOS and IL12A were highlighted as key genes, both significantly downregulated in DN, with potential therapeutic implications.

  • 4

    The mTORC1 signaling pathway was identified as a critical mechanism in DN pathogenesis, influencing immune microenvironment remodeling.

  • 5

    This research integrates genomic and microbiota data to propose novel therapeutic targets for DN, emphasizing the gut microbiota-metabolite connection.

Original Source(s)

Therapeutic targets for diabetic nephropathy identified by druggable genome mendelian randomization: the role of the gut microbiota-metabolite axis

  • by Ling Niu, Rong Ma, Cuijuan Miao, Fang Liu, Boyi Li

  • May 8, 2026

Related Content

Evaluating the Effectiveness of Rituximab in Children with Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome Associated with MCD or FSGS

Small patients, big gaps: why adult CRRT timing evidence does not translate to children

Is creatine kinase a valid aid in early cardiac muscle damage detection during treatment for childhood acute lymphoblastic leukemia? A case report